chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I ended up having loose stools a couple hours after receiving the vaccine. I left work early because of this symptom. The next day I felt nauseous, still had loose stools and abdominal pain. This continued over a week, but I did call my GI doctor and they performed a CT scan. The CT scan showed abdominal inflammation in my colon. They gave me Zofran and put me on a liquid diet. My stool sample came back with elevated inflammation markers. My CEB rates were elevated. I did have a f/u and they said that I had been in remission with my Crohn's. The reason my doctor told me about being in remission is because he felt that my symptoms were a reaction to the vaccine. I started to feel better after a week of receiving the Zofran and being on the liquid diet.
Light headed, Achy, Flu Like Symtoms, Blood Pressure dropped to 98/54  and Ears Pounding the day after vaccination.   The second day after vaccination, she had a red rash from her neck down to under her arms and along her rib cage.  She notified her physician and they did not treat her or see her.
Patient received Flu and Pneumovax vaccination At 11:45 AM. Patient went home. 2 hours later patient went out shopping got dizzy and fainted.
Mother called on 1/27/05 stating that she took pt(and twin sibling- also reported on) to E.D. on 1/26/05 which was one day after patient received vaccines due to the following symptoms:  "bulging soft spot", increased sleep, decreased appetite, low grade fever up to 100.7 (rectal), and mild cough. E.D. diagnosed pt (per mother's report) as "possible reaction to DTaP".  Pt was sent home from the E.D.
Collapse, breathelessness and exhaustion, SLept for 8 days, day and night.  Left leg swollen , painful and extreme. Had doppler, EKG. Had a four pound weight gain in two days.
Pt states had burning at time of injection and within 20 minutes, had itching at elbow. At 11:20, itching at site of injection and down to elbow. Area around site was reddened.
pt recv vax 23APR98 & fever onset 30APR inc & dec x 48hr;rash onset 3MAY lasted 24hr;crabby for 1wk more  4MAY-11MAY especially @ noc & seems joints hurt;
lost his smell for 2 weeks; This is a spontaneous report from a contactable consumer (patient) or other non HCP. A male patient of an unspecified age received BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number and Expiration date was not reported), via an unspecified route of administration on an unspecified date as 2nd dose, single dose for covid-19 immunisation. The patient medical history and concomitant medications was not reported. The patient received BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number and Expiration date was not reported), via an unspecified route of administration on an unspecified date as 1st dose, single dose for covid-19 immunisation. On unspecified date, after the second dose, patient lost his smell for 2 weeks. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient states she was to receive moderna. She did not notice till later when she needed to show her proof of vaccination. Patient is upset. No reaction to vaccine
Rash, described as red bumps by mom on abdomen, back (small area); t100 started evening of immun 23SEP91; rash lasted approx 24 hrs & temp lasted approx 4-5days; loss of appetite approx 24hrs beginning evening of 23SEP91;
Information has been received from a nurse practitioner concerning a 60 year old adult female with no past medical history and no known allergies who on 11/19/03 at 9:00 AM was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine. There was no illness at the time of vaccination. On approximately 11/20/03, within 24 hours, the patient developed cellulitis. On 11/21/03, the patient presented to the doctor's office and was given amoxicillin (+) clavulanate potassium for treatment. There was no product quality complaint involved. No other information was available at the time of this report. Follow up information received from a nurse practitioner indicated that on 11/19/03 at 12 noon, three hours after injection, the patient noted pain and swelling at the site. No adenopathy was noted. The patient was started on amoxicillin (+) clavulanate potassium for 5 days on 11/20/03 and the condition resolved. No relevant diagnostic tests or laboratory data were obtained. Upon internal review, cellulitis was considered an other important medical event (OMIC). No further information is expected.
Left axillary lymphadenopathy ( marked edema, pain ,warmth and slight erythema).
Patient received 2nd Shingrix vaccine 5/6/21 around 3pm. She started to feel lightheaded at her office about 45min later and asked her husband to pick her up. She laid down at home and about an hour after vaccination began to feel tingling in lips/tongue. Her speech began to slur. She called the pharmacy and was advised to call 911. Because she lives very close to the hospital, her husband drove her to the hospital where she received epinephrine injection and was sent home with a prescription for 20mg prednisone twice daily for 3 days and diphenhydramine every 6 hours for 3 days.
Information has been received from a health professional concerning a patient who was vaccinated with a dose of ROTATEQ. The nurse reported that the patient may have received the first dose of ROTATEQ on 19-SEP-2008 at 16 weeks. It was reported the office documentation listed the patient's first dose was on 17-JUL-2008, but the patient's mother stated the first dose was on 19-SEP-2008. No adverse symptoms were reported. No other information was given. A product quality complaint was not involved. Additional information has been requested.
random cold hands and legs; chills; fever; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL COLDNESS (random cold hands and legs), CHILLS (chills) and PYREXIA (fever) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and 028L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 16-Feb-2021, the patient experienced CHILLS (chills) and PYREXIA (fever). On 01-Mar-2021, the patient experienced PERIPHERAL COLDNESS (random cold hands and legs). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at a dose of 1 dosage form. On 17-Feb-2021, CHILLS (chills) and PYREXIA (fever) had resolved. At the time of the report, PERIPHERAL COLDNESS (random cold hands and legs) had not resolved.            No concomitant medication was provided by the reporter.  Action taken with mRNA1273 Moderna vaccine was Not Applicable     This case was linked to US-MODERNATX, INC.-MOD-2021-076306 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-076306:Crossed linked
Arm is very hot, like you can fry an egg on it; Chills for 15-20 minutes and then go supper hot; Sore arm went down to elbowand into my shoulder; Arm is really sore, started to boom boom; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (Arm is very hot, like you can fry an egg on it), FEELING OF BODY TEMPERATURE CHANGE (Chills for 15-20 minutes and then go supper hot), ARTHRALGIA (Sore arm went down to elbowand into my shoulder) and PAIN (Arm is really sore, started to boom boom) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure and Thyroid disorder NOS.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced FEELING HOT (Arm is very hot, like you can fry an egg on it), FEELING OF BODY TEMPERATURE CHANGE (Chills for 15-20 minutes and then go supper hot), ARTHRALGIA (Sore arm went down to elbowand into my shoulder) and PAIN (Arm is really sore, started to boom boom). At the time of the report, FEELING HOT (Arm is very hot, like you can fry an egg on it), FEELING OF BODY TEMPERATURE CHANGE (Chills for 15-20 minutes and then go supper hot), ARTHRALGIA (Sore arm went down to elbowand into my shoulder) and PAIN (Arm is really sore, started to boom boom) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
In the morning of 9/20/2021 felt cold with a low grade fever, nausea, cough was worse, sore throat, progressively tired as time went on,  9/21/2021 vomited and stayed home. 9/22/2021Urgent Care sought test from doctor and took a CoVid Test. Results negitive. 9/30/2021 Sought care from PC Nurse and took another CoVid test. Negitive. Blood work was taken, results was inconclusive, no treatment given, Currently trying to schedule an appt. with PCP.
chills; headache; stomachache; This is a spontaneous report from a contactable consumer. An adult female patient in her late 40's or early 50's received pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) (PREVNAR 13), via an unspecified route of administration in right arm/shoulder area on 29Sep2020 at a single dose for immunization and influenza vaccine via an unspecified route of administration in left arm/shoulder area on 29Sep2020 at an unspecified dose for immunization, in the workplace clinic.The patient's medical history and concomitant medications were not reported. On an unspecified date in Sep2020, the patient was having chills, headache, and stomachache and was going home because she couldn't get warm. The outcome of the events was recovering.  No follow-up attempts are needed; Information about the lot/ batch number could not be obtained.
patient called  about 2 hours after vaccination complaining about muscle tingle on both arms, dizziness and difficulty sitting and standing. advised patient to call md/report to the emergency department.
Patient had a red, hot and swollen arm from the site of injection to her elbow.  She received an antibiotic from the emergency room.  She picked up antibiotic two days after injection of vaccine.
Red blotches on face and chest. Patient contacted dermatologist via phone and was prescribed ELOCON Crm to apply twice daily for one week
MIGRAINE; This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's concurrent conditions included menstrual migraines, and neck issues.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 23-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 23-MAR-2021, the subject experienced migraine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of migraine was not reported. This report was non-serious.
A rash occurred on my neck around 9pm on 4/25. Two days later the rash has progressed from my neck up to my face. Extremely itchy.
MEMORY LOSS; BRUISE IN PALM OF HAND; LEFT HAND SWOLLEN; ARM SENSITIVE; LEFT HAND PAIN; INAPPROPRIATE SCHEDULE OF VACCINE ADMINISTERED; OFF LABEL USE; This spontaneous report received from a patient concerned an adult female. The patient's height, and weight were not reported. The patient's concurrent conditions included: rheumatoid arthritis.  The patient received two doses of covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, intramuscular, batch number: unknown expiry: unknown) dose was not reported, 1 total, administered on 09-MAR-2021 and on an unspecified date in 2021 for prophylactic vaccination which was off label use as inappropriate use of vaccine administered. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.  On an unspecified date, the patient experienced memory loss, bruise in palm of hand with the following two doses of covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient had non company suspect as adalimumab (form of admin not reported, subcutaneous, batch number was not reported) dose was not reported, administered on an unspecified date for rheumatoid arthritis.  The patient received booster dose of Moderna Covid-19 vaccine (Elasomeran) (Dose number in series 2) (form of admin not reported, intramuscular, batch number: unknown, expiry: unknown) dose was not reported, administered on 11-JAN-2022 for prophylactic vaccination. On an unspecified date patient had left hand swollen, left hand pain and arm sensitive  with the following Moderna Covid-19 vaccination (Dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s, and elasomeran was not applicable; and action taken with adalimumab was not reported. The patient had not recovered from arm sensitive, and the outcome of memory loss, bruise in palm of hand, left hand swollen, left hand pain, off label use and inappropriate schedule of vaccine administered was not reported. This report was non-serious.
FEVER; TIRED; This spontaneous report received from a patient concerned a female of unspecified age The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company was unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced fever, and tired. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever, and tired. This report was non-serious.
Moderna adult given as booster dose (.25) to 15 year old.   No reaction noted.
Second dose of Moderna COVID vaccine 3/17/21, onset of swelling of conjunctiva and blurry vision in both eyes on 3/18 with progression of vision loss to no light perception in left eye by 3/19 AM. Sent to ED and admitted to hospital after outpatient ophthalmology exam and started treatment with 1g methylprednisolone IV daily x5 days on 3/20. As of 3/22 eye pain had subsided but no improvement in vision. Has been in hospital 4 days at this point with uncertain discharge date.
Moderna COVID-19 Vaccine  Swelling at injection site, red and raised with aching pain through the left shoulder and neck
No additional AE; HCP called in to report a patient was prescribed PNEUMOVAX 23, and received an expired dose. HCP wanted to know of any adverse effects of receiving expired dose of vaccine. MIR on 02368968. No additional AE/PQC.; This spontaneous report was received from a nurse, referring to a 4-year-old patient with unknown gender. The patient's concomitant therapy, concurrent conditions, medical history and drug reactions/allergies were not reported.  On 10-APR-2023, the patient was prescribed pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) and was vaccinated with an expired dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (lot number U027357 has been verified to be a valid lot number, expiration date was reported as 25-MAR-2023, 0.5 milligram (mg) /x1 only, route and anatomical location were not provided) for prophylaxis (expired product administered). No additional adverse event (AE) reported (no adverse event). The reporter wanted to know of any adverse effects of receiving expired dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23).
This spontaneous report was received from a physician via an unspecified reporter referring to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 10-MAR-2016, the patient was vaccinated with a dose of improperly stored PNEUMOVAX 23 "10 PK 0.5mL SD-PFS LLokwTip 10 PK" and lot number L014876 with expiration date of 13-JAN-2017 (route of administration and anatomical location were not reported), which was stored at a lowest recorded temperature of 27F for 1764 hours. The vaccine status was reported as excursion and the storage criteria and the vaccine excursion were reported as "Refrigerator (R)". No concomitant therapies nor adverse effect were reported. No product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested.
The of the shot I had no reaction, the day after the shot I felt a small tickle in my throat and the arm I got the shot in hurt a bit, this day I took a benadryl before bed that night and felt fine no issues till the 13th of January I woke with my left arm sore,  and at the shot area my arm was noticeably swollen, hot to the touch, my throat was closing and I was itchy all over my entire body.   I called the ER at the hospital and explained what my systeoms were and the person I spoke with said it was my choice to either come to the ER or if I wanted to try benadryl again. I opted to take the benadryl at the time then I took a 2nd Benadryl at bed time. Since then I have a little bit of a sore throat.
Information has been received from an advanced practice registered nurse (A.P.R.N.) concerning a 19 year old female patient with allergy to penicillin and osteopenia, vitamin B and D deficiency, who on 06-JUN-2011, was vaccinated with a first dose of GARDASIL, intramuscular (lot number 668554/0306AA, expiration date 10-MAY-2013), (dose not reported), on 15-AUG-2011, was vaccinated with a second dose of GARDASIL, (dose, route, lot number were not reported). Concomitant therapy included ethinyl estradiol (+) etonogestrel. On 18-AUG-2011, after receiving the second dose of GARDASIL the patient experienced flu like symptoms including body aches, sore neck, fever and fatigue. The patient then developed pain, redness, blister and swelling on her genital area. It was reported that the patient could not walk and had difficulty urinating. The patient was given VALTREX and resolved few days later, on 01-SEP-2011. The patient sought unspecified medical attention. Following laboratory diagnostics studies were performed: HSV culture, HSV1 and HSV2 IGG and IGM (results not provided). Could not walk was considered to be disabling. Additional information has been requested.
Approximately 2 weeks after vaccination, an injection site reaction occurred. Arm swelling, skin is bright red, hot. Symptoms have persisted for 20 hours at this time. Some itching, "numb" feeling when touched.
2MAY98 began to devel a faint rash;began oral typhoid 3MAY98;rash seemed to get worse;went to clinic 4MAY98;saw MD & given antihistamine;6MAY98 saw MD because rash worse;rash on throat, arms, trunk & stomach;rash red, sl raised, pruritus;
Malaise, loss of appetite, fever, chills, muscle aches, headache, fatigue, pain at injection site. Began within 1-2 hours and worsened into evening, when severe symptoms became evident. 24 hours in bed, resolved by day 2.
This spontaneous report was received from a medical assistant and refers to a an approximately 20 unspecified patients of unknown demographics. No information regarding the patients' pertinent medical history, concomitant therapies and drug reaction or allergies was provided. On an unknown date, the patients were vaccinated with improperly stored doses of VARIVAX lot # N022978, expiry date 12-SEP-2018 (dose, route of administration were dot reported) for prophylaxis. The doses of vaccine were stored in unspecified out of range temperature in an unspecified time frame. Previous temperature excursions were detected over 30 days. Digital data logger was involved. No adverse effects were reported. Additional information was received from the medical assistant on 19-JAN-2018. Identifiers for some of the patients were provided. The following temperature excursions were reported for the lot number N022978 of VARIVAX: Temperature excursions between 6°F to 14°F (-14°C to -10°C) on 23-NOV-2017 (3 hours),  26-NOV-2017 (3 hours), 28-NOV-2017 (3.5 hours), 01-DEC-2017 (3 hours), 04-DEC-2017 (3 hours), 07-DEC-2017 (2 hours), 10-DEC-2017 (2 hours), 13-DEC-2017 (2 hours), 16-DEC-2017 (2 hours) and on 18-DEC-2017 (1 hour);  and between 15°F to 46°F (-9°C to 8°C) on 24-NOV-2017 (4 hours),  25-NOV-2017 (3 hours), 27-NOV-2017 (4 hours), 29-NOV-2017 (3 hours), 30-NOV-2017 (3.5 hours), 02-DEC-2017 (3 hours), 03-DEC-2017 (3.5 hours), 05-DEC-2017 (3 hours), 06-DEC-2017 (2.5 hours), 08-DEC-2017 (2.5 hours), 09-DEC-2017 (2.5 hours), 11-DEC-2017 (2 hours), 12-DEC-2017 (2 hours), 14-DEC-2017 (1.5 hour), 15-DEC-2017 (2 hours), and on 17-DEC-2017 (2.5 hours). The vaccines underwent a total of 69 hours of temperature exposure. Additionally, the reporter stated that one of the patients was vaccinated on 05-JAN-2018. This is one of several cases reported by the same reporter.; Sender's Comments: US-009507513-1801USA006569: Original Case : 1801USA006569.
Doses administered after more than 1 temperature excursion; It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Mar-2021 at 3:07 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 27-Mar-2021 at 3:07 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 67.50 Concomitant products were not provided.  For batch 019B21A, on 27-Mar-2021, excursion time were 9 AM and 10AM, temperature was 35 for both timings, condition of vaccine prior to vaccination was not frozen, vaccine was moved to fridge on 23-Mar-2021, vial was moved to clinic on 27-Mar-2021, 20 vial was moved to clinic. Vaccine BUD date was 22-Apr-2021.  It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34- or 35-degree F.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic. Temperature recordings were taken by using a traceable temperature monitor at every hour. After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  No treatment information was provided.